The Motley Fool

ESG investing: should I buy these 2 UK shares?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Hands of woman with many shopping bags
Image source: Getty Images

ESG investing has boomed. Many investors are now looking at the environmental, social, and corporate governance records of the companies they choose. Financial prospects alone are not the only consideration.

Below I reveal two shares I have been assessing for my portfolio, both from an ESG and financial perspective.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

Vaccine champion

One of the companies I am considering is AstraZeneca (LSE: AZN). Why? Its focus on providing vaccines in the key phase of the pandemic to developing countries without profit ticks the social box in my view.

The pharma giant’s success launching its vaccine at speed compares to its more mixed business results in recent years. Along with dissatisfaction at high executive pay, that helps to explain why its shares have fallen 9% over the past year. Could now be the time to add it as an ESG investing choice to my portfolio?

Pros and cons

The vaccine has pushed AstraZeneca onto the front pages, but its business is much broader than that.

In the past couple of years, the company has reversed a falling revenue trend. Profits also more than doubled. That is driven by more than just its vaccine development, though ultimately it will help revenue and profits.

The company has a strong research and development capability. The years it spent building up its pipeline of new drugs finally seems to be paying off. Releases of products such as Lynparza have generated multibillion pound sales and the company is lining up a successor.

But AstraZeneca does face risks. Pipeline development is very costly and there can be unforeseen disappointments as clinical trials progress. That can lead to falling revenues.

Given AstraZeneca’s quality portfolio and future pipeline, I would consider picking it as an ESG investing option for my portfolio.

ESG investing in recycling

A second choice I would consider for ESG investing in my portfolio is Biffa (LSE: BIFF).

The name is familiar from bin lorries. Biffa already positions itself as the leading sustainable waste management company in the UK. It announced yesterday it would be buying more waste management and recycling assets from Viridor.

The company is set to publish its annual results next week. In a trading update in March, it said that its second half performance surpassed its base case planning scenario.

Biffa share price risks

One concern I have about Biffa is its debt load. Like many companies, the company has borrowed to help finance itself. Its estimated net debt of £440m-£460m at the end of March makes the company more highly leveraged than I would like. That is still within its loan covenants. But servicing this debt risks lower future returns to shareholders.

I am also concerned that customers such as councils could look to cut budgets in coming years. That would be a risk to the company’s profits.

My next ESG investing move

I have been looking at both AstraZeneca and Biffa for my portfolio. Their ESG credentials are sufficient for me. But I think ESG investing involves financial considerations too. I would never buy a share just because it had a strong ESG story.

I would consider buying AstraZeneca for my portfolio now. But Biffa’s debt pile puts me off the shares for now. I will wait and take the opportunity to study next week’s results closely.

Our 5 Top Shares for the New “Green Industrial Revolution"

It was released in November 2020, and make no mistake:

It’s happening.

The UK Government’s 10-point plan for a new “Green Industrial Revolution.”

PriceWaterhouse Coopers believes this trend will cost £400billion…

…That’s just here in Britain over the next 10 years.

Worldwide, the Green Industrial Revolution could be worth TRILLIONS.

It’s why I’m urging all investors to read this special presentation carefully, and learn how you can uncover the 5 companies that we believe are poised to profit from this gargantuan trend ahead!

Access this special "Green Industrial Revolution" presentation now

christopherruane has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.